For state Medicaid agencies that opt to participate in the model, implementation will be on a rolling basis from May 1, 2026 through January 1, 2027
Other lipid-lowering therapies include: Ezetimibe : Reduces LDL cholesterol by approximately 1520% by inhibiting intestinal cholesterol absorption Bempedoic acid : Lowers LDL cholesterol by 15-25%, often used with ezetimibe when statins are contraindicated or not tolerated PCSK9 inhibitors : Achieve dramatic LDL reductions of 5060%, reserved for patients with very high cardiovascular risk or familial hypercholesterolaemia Fibrates : Primarily target triglycerides (reductions of 3050%) with modest effects on LDL cholesterol Icosapent ethyl : A prescription-grade omega-3 fatty acid that may be used in selected high-risk patients
Recent studies of isolated L-cells (95) and a L-cell derived cell line, GLUTag cells, have shown stimulation of GLP-1 secretion by glucose acting to inhibit K+ channels as in islet beta cells, by activation of the SGLT-1 transporter leading to depolarization (91), or activation of sweet taste receptors (T1R2 / T1R3) which activate Gq and PLC
Red-flag symptoms such as severe abdominal pain, persistent vomiting, or jaundice require immediate cessation and urgent medical attention
These studies all showed that GLP-/GIP dual agonists had similar effects on lipid metabolism to GLP-1, and even had better effects on lipid reduction and weight loss
